INSUBCONTINENT EXCLUSIVE:
The Serum Institute of India, which had paused phase 2 and phase 3 trials of the Oxford University's vaccine, received
Hopkins University (JHU), India is the second country in the world after the US to have reported over 50 lakh cases
of volunteers for the phase 2 and phase 3 trials of the Oxford University's vaccine candidate following reports of adverse reactions to the
in 11 daysThe total number of coronavirus cases in the country mounted to 50,20,359 on Wednesday, while the toll climbed to 82,066 with a
and another 59 days to surpass 10 lakh
The total coronavirus cases jumped from 10 lakh to 20 lakh in 21 days and raced past 30 lakh in another 16 days
persons have so far recuperated from the virus
disease.The recovery rate now stands at 78.53 percent, up from 77.77 percent a week ago (9 September), showed the health ministry's data
The fatality rate is now at 1.63 percent, the ministry said.The country now has 9,95,933 active cases of COVID-19, comprising 19.84 percent
The state's case count has doubled since the start of September, the report stated
Chhattisgarh on Tuesday recorded its highest single-day spike of 3,450 coronavirus cases, taking the state's total cases to 70,777,Of the
Andhra Pradesh, 68 from Tamil Nadu, 59 from West Bengal and 36 from Delhi.Of the total 82,066 fatalities due to COVID-19, Maharashtra
11,16,842 samples were tested on Tuesday.SII gets DCGI nod to resume vaccine trialsEven as the country's coronavirus count continued an
the Rajya Sabha that 13 clinical trials of repurposed drugs have been also undertaken to build a portfolio of therapeutic options for
COVID-19 patients.Meanwhile, the DCGI allowed SII to resume the phase 2 and 3 trials of the vaccine jointly developed by Oxford University
potential volunteers and providing additional information to them.The regulator also instructed the Pune-based firm to closely monitor
volunteers who receive the shot for any adverse reactions.The DCGI had on 10 September issued a show-cause notice to the Serum Institute of
India, which had chosen no to halt the clinical trials in India even though trials had reportedly been paused in various countries like US,
The countries had halted the trials after the Swedish firm had reported an unexplained illness in one of the volunteers in the UK.Russia
strikes deal with Dr Reddy's Laboratoeis to distribute 100 million doses of Sputnik VIn another development on the vaccine front, Russia has
Sputnik V vaccine in India.Press secretary Arseniy Palagin told news agency The Asociated Press that the 100 million doses of the
told the Indian Express.Palagin also said that the Russian Direct Investment Fund (RDIF) was in talks with several other Indian companies
for manufacturing the vaccine.Last week, Dr VK Paul, NITI Aayog member who also heads the national task force on COVID-19 vaccines, had said
that India was considering Russia's requests for conducting the phase three trials in India and that an agreement will be "good for both the
across the globe, according to the JHU's coronavirus tracker.With inputs from agencies
